Clinical management and emerging therapies of FGFR3-related skeletal dysplasia in childhood

키워드

참고문헌 (59)

1. Du X, "Role of FGFs", FGFRs in skeletal development and bone regeneration, 2012, pp.227, 3731~3743
2. Foldynova-Trantirkova S, "Sixteen years and counting : the current understanding of fibroblast growth factor receptor 3(FGFR3)signaling in skeletal dysplasias", Hum Mutat, 33, pp.29~41 (2012)
3. Toydemir RM, "A novel mutation in FGFR3 causes camptodactyly, tall stature, and hearing loss(CATSHL)syndrome", Am J Hum Genet, 79, pp.935~941 (2006)
4. Makrythanasis P, "A novel homozygous mutation in FGFR3 causes tall stature, severe lateral tibial deviation, scoliosis, hearing impairment, camptodactyly, and arachnodactyly", Hum Mutat, 35, pp.959~963 (2014)
5. Sargar KM, "Imaging of skeletal disorders caused by fibroblast growth factor receptor gene mutations", Radiographics, 37, pp.1813~1830 (2017)
6. Marzin P, "New perspectives on the treatment of skeletal dysplasia", Ther Adv Endocrinol Metab, 11, pp.2042018820904016~ (2020)
7. Legeai-Mallet L, "Novel therapeutic approaches for the treatment of achondroplasia", Bone, 141, pp.115579~ (2020)
8. Laederich MB, "Achondroplasia : pathogenesis and implications for future treatment", Curr Opin Pediatr, 22, pp.516~523 (2010)
9. Narayana J, "FGFR3 biology and skeletal disease", Connect Tissue Res, 56, pp.427~433 (2015)
10. Deng C, "Fibroblast growth factor receptor 3 is a negative regulator of bone growth", Cell, 84, pp.911~921 (1996)
11. Eswarakumar VP, "Cellular signaling by fibroblast growth factor receptors", Cytokine Growth Factor Rev, 16, pp.139~149 (2005)
12. Segev O, "Restrained chondrocyte proliferation and maturation with abnormal growth plate vascularization and ossification in human FGFR-3(G380R)transgenic mice", Hum Mol Genet, 9, pp.249~258 (2000)
13. Colvin JS, "Skeletal overgrowth and deafness in mice lacking fibroblast growth factor receptor 3", Nat Genet, 12, pp.390~397 (1996)
14. Escobar LF, "A second family with CATSHL syndrome : confirmator y report of another unique FGFR3 syndrome", Am J Med Genet A, 170, pp.1908~1911 (2016)
15. Offiah AC, "Radiological diagnosis of the constitutional disorders of bone. As easy as A, B, C?", Pediatr Radiol, 33, pp.153~161 (2003)
16. Horton WA, "Achondroplasia", Lancet, 370, pp.162~172 (2007)
17. Waller DK, "The population-based prevalence of achondroplasia and thanatophoric dysplasia in selected regions of the US", Am J Med Genet A, 146A, pp.2385~2389 (2008)
18. Orioli IM, "Effect of paternal age in achondroplasia, thanatophoric dysplasia, and osteogenesis imperfecta", Am J Med Genet, 59, pp.209~217 (1995)
19. Bellus GA, "Achondroplasia is defined by recurrent G380R mutations of FGFR3", Am J Hum Genet, 56, pp.368~373 (1995)
20. Legare JM, "GeneReviews((R))" (2022), University of Washington
21. Kubota T, "Clinical practice guidelines for achondroplasia", Clin Pediatr Endocrinol, 29, pp.25~42 (2020)
22. Hoover-Fong J, "Health supervision for people with achondroplasia", Pediatrics, 145, pp.e20201010~ (2020)
23. Horton WA, "Standard growth curves for achondroplasia", J Pediatr, 93, pp.435~438 (1978)
24. Hecht JT, "Mortality in achondroplasia", Am J Hum Genet, 41, pp.454~464 (1987)
25. Panda A, "Skeletal dysplasias : a radiographic approach and review of common non-lethal skeletal dysplasias", World J Radiol, 6, pp.808~825 (2014)
26. McKusick VA, "Observations suggesting allelism of the achondroplasia and hypochondroplasia genes", J Med Genet, 10, pp.11~16 (1973)
27. Prinos P, "A common FGFR3 gene mutation in hypochondroplasia", Hum Mol Genet, 4, pp.2097~2101 (1995)
28. Rousseau F, "Clinical and genetic heterogeneity of hypochondroplasia", J Med Genet, 33, pp.749~752 (1996)
29. Xue Y, "FGFR3 mutation frequency in 324 cases from the International Skeletal Dysplasia Registry", Mol Genet Genomic Med, 2, pp.497~503 (2014)
30. Glasgow JF, "Hypochondroplasia", Arch Dis Child, 53, pp.868~872 (1978)
31. Arenas MA, "FGFR3-related hypochondroplasia : longitudinal growth in 57 children with the p. Asn540Lys mutation", J Pediatr Endocrinol Metab, 31, pp.1279~1284 (2018)
32. Wynne-Davies R, "Achondroplasia and hypochondroplasia. Clinical variation and spinal stenosis", J Bone Joint Surg Br, 63B, pp.508~515 (1981)
33. Wynne-Davies R, "The frequency of mental retardation in hypochondroplasia", J Med Genet, 28, pp.644~ (1991)
34. Linnankivi T, "Neuroimaging and neurological findings in patients with hypochondroplasia and FGFR3 N540K mutation", Am J Med Genet A, 158A, pp.3119~3125 (2012)
35. Orioli IM, "The birth prevalence rates for the skeletal dysplasias", J Med Genet, 23, pp.328~332 (1986)
36. Donnelly DE, "The prevalence of thanatophoric dysplasia and lethal osteogenesis imperfecta type II in Northern Ireland-a complete population study", Ulster Med J, 79, pp.114~118 (2010)
37. French T, "GeneReviews®" (2022), University of Washington
38. Hurst JA, "Skeletal dysplasias", Semin Fetal Neonatal Med, 10, pp.233~241 (2005)
39. MacDonald IM, "Growth and development in thanatophoric dysplasia", Am J Med Genet, 33, pp.508~512 (1989)
40. Nikkel SM, "Growth and development in thanatophoric dysplasia-an update 25 years later", Clin Case Rep, 1, pp.75~78 (2013)
41. Baker KM, "Long-term survival in typical thanatophoric dysplasia type 1", Am J Med Genet, 70, pp.427~436 (1997)
42. Nakai K, "Seborrhoeic keratoses and acanthosis nigricans in a long-term survivor of thanatophoric dysplasia", Br J Dermatol, 163, pp.656~658 (2010)
43. Katsumata N, "G370C mutation in the FGFR3 gene in a Japanese patient with thanatophoric dysplasia", Endocr J, 45(Suppl), pp.S171~S174 (1998)
44. Kuno T, "Markers for bone metabolism in a long-lived case of thanatophoric dysplasia", Endocr J, 47(Suppl), pp.S141~S144 (2000)
45. Tavormina PL, "A novel skeletal dysplasia with developmental delay and acanthosis nigricans is caused by a Lys650Met mutation in the fibroblast growth factor receptor 3 gene", Am J Hum Genet, 64, pp.722~731 (1999)
46. Zankl A, "Prenatal and postnatal presentation of severe achondroplasia with developmental delay and acanthosis nigricans(SADDAN)due to the FGFR3Lys650Met mutation", Am J Med Genet A, 146A, pp.212~218 (2008)
47. Bellus GA, "Severe achondroplasia with developmental delay and acanthosis nigricans(SADDAN) : phenotypic analysis of a new skeletal dysplasia caused by a Lys650Met mutation in fibroblast growth factor receptor 3", Am J Med Genet, 85, pp.53~65 (1999)
48. Harada D, "Final adult height in long-term growth hormone-treated achondroplasia patients", Eur J Pediatr, 176, pp.873~879 (2017)
49. Massart F, "Height outcome of short children with hypochondroplasia after recombinant human growth hormone treatment : a metaanalysis", Pharmacogenomics, 16, pp.1965~1973 (2015)
50. 고경래, "Surgical Results of Limb Lengthening at the Femur, Tibia, and Humerus in Patients with Achondroplasia", Clinics in Orthopedic Surgery, 11(2), pp.226~232 (2019), 대한정형외과학회
51. Al Shaer D, "2021FDA TIDES(Peptides and Oligonucleotides)Harvest", Pharmaceuticals(Basel), 15, pp.222~ (2022)
52. Cappellen D, "Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas", Nat Genet, 23, pp.18~20 (1999)
53. Krejci P, "Interaction of fibroblast growth factor and C-natriuretic peptide signaling in regulation of chondrocyte proliferation and extracellular matrix homeostasis", J Cell Sci, 118, pp.5089~5100 (2005)
54. Yasoda A, "Overexpression of CNP in chondrocytes rescues achondroplasia through a MAPK-dependent pathway", Nat Med, 10, pp.80~86 (2004)
55. Suhasini M, "Cyclic-GMP-dependent protein kinase inhibits the Ras", Mitogen-activated protein kinase pathway, 1998, pp.18, 6983~6994
56. Savarirayan R, "Once-daily, subcutaneous vosoritide therapy in children with achondroplasia : a randomised, double-blind, phase 3, placebo-controlled, multicentre trial", Lancet, 396, pp.684~692 (2020)
57. Unger S, "Current care and investigational therapies in achondroplasia", Curr Osteoporos Rep, 15, pp.53~60 (2017)
58. Matsushita M, "Meclozine promotes longitudinal skeletal growth in transgenic mice with achondroplasia carrying a gain-of-function mutation in the FGFR3 gene", Endocrinology, 156, pp.548~554 (2015)
59. Yamashita A, "Statin treatment rescues FGFR3 skeletal dysplasia phenotypes", Nature, 513, pp.507~511 (2014)

관련 논문AI추천